HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collins, J J Articles by Shepperly, D Search for Related Content PubMed PubMed Citation Articles by Collins, J J Articles by Shepperly, D

Lymphohaematopoeitic cancer mortality among workers with benzene exposure

¹ Solutia, 575 Maryville Centre Drive, St Louis, MO 63141, USA
² St Louis University
³ Retired from Monsanto

Correspondence to:
Correspondence to:
Dr J J Collins, Dow Chemical, Building 1803, Midland, Michigan 48674, USA;
jjcollins{at}dow.com

Lymphohaematopoeitic cancer mortality was examined among 4417 workers at a chemical plant by cumulative and peak benzene exposure. There was little evidence of increasing risk with increasing cumulative exposure for all leukaemias or acute non-lymphocytic leukaemias (ANL), or the other lymphohaematopoeitic cancers with the exception of multiple myeloma. For multiple myeloma, the SMRs were 1.1 (95% CI 0.3 to 2.5) in the non-exposed group, 1.4 (95% CI 0.2 to 5.1) in the <1 ppm-years, 1.5 (95% CI 0.2 to 5.4) in the 1–6 ppm-years, and 2.6 (95% CI 0.7 to 6.7) in the >6 ppm-years group. We found no trends by peak exposures for any of the cancers. However, when peak exposures over 100 ppm for 40 or more days were considered, the observed number of all leukaemias (SMR = 2.7, 95% CI 0.8 to 6.4), ANL (SMR = 4.1, 95% CI 0.5 to 14.9), and multiple myeloma (SMR = 4.0, 95% CI 0.8 to 11.7) were greater than expected. While the observed number of deaths is small in this study, the number of peak exposures greater than 100 ppm to benzene is a better predictor of risk than cumulative exposure. The dose rate of benzene and a threshold for exposure response may be important factors for evaluating lymphohaematopoietic risk.

Keywords: benzene; leukaemia; multiple myeloma; exposure estimation

Abbreviations: ANL, acute non-lymphocytic leukaemia; CI, confidence interval; SMR, standardised mortality ratio

This article has been cited by other articles:

				C Steinmaus, A H Smith, R M Jones, and M T Smith Meta-analysis of benzene exposure and non-Hodgkin lymphoma: biases could mask an important association Occup. Environ. Med., June 1, 2008; 65(6): 371 - 378. [Abstract] [Full Text] [PDF]

				P. F INFANTE Benzene Exposure and Multiple Myeloma: A Detailed Meta-analysis of Benzene Cohort Studies. Ann. N.Y. Acad. Sci., September 1, 2006; 1076: 90 - 109. [Abstract] [Full Text] [PDF]

				T Sorahan, L J Kinlen, and R Doll Cancer risks in a historical UK cohort of benzene exposed workers Occup. Environ. Med., April 1, 2005; 62(4): 231 - 236. [Abstract] [Full Text] [PDF]

				S. M. Rappaport, L. L. Kupper, and Y. S. Lin On the Importance of Exposure Variability to the Doses of Volatile Organic Compounds Toxicol. Sci., February 1, 2005; 83(2): 224 - 236. [Abstract] [Full Text] [PDF]